CV Therapeutics
Executive Summary
Completes $6.9 mil. round of private financing, bringing total raised through two financing rounds since research firm's establishment in 1992 to $13 mil. CV Therapeutics, based in Mountain View, Calif., will use the proceeds to further R&D on its cardiovascular therapies. Lead product is CVT-1 for cholesterol reduction, which is forecast to enter human clinical in late 1993.